Aug. 29 at 11:36 AM
$COYA Enrollment happening September 23rd to October 15th 120 patients. The stock does not resemble the completion of 120 patients. 3 years essentially been
$4.50 to
$5.00 per share.
I would say the completion of the enrollment should elevate our stock price but not sure entirely as the acceptance on Wednesday of Abatacept in India was short lived.
I will not do what I did 3 years ago again like I did with PRVB...It feels like the same type setup. I bought PRVB
$10 TO
$14....Held it 10 months I believe sold at
$9..I was the smart guy as it dropped to
$6....I thought I was so smart....went out on a Friday at
$6.25 thought about buying again...I didnt only to get bought by Sanofi who put in 35m initially...
$25 in cash... 4x...
This will Trade between
$4.X to
$6.X whether it is a deal or readout...For me I believe this works....The price is absurd hence the frustration.
Bought 3000 more on Friday....LONG AND STRONGER.
